MetaCap

Sarepta Therapeutics (SRPT) vs Tyra Biosciences (TYRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tyra Biosciences (TYRA) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 4.7% versus a loss of 24.6%. Over five years, TYRA leads with a -15.7% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SRPT-24.65%TYRA-4.73%
+93%+31%-30%
Nov 21, 20251 yearNov 20, 2026
SRPT-83.34%TYRA-16.17%
+110%+8%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SRPT versus TYRA key metrics
MetricSRPTTYRA
Share price$13.33$20.12
Market cap$1.43B$1.39B
1-day change-5.93%+1.98%
YTD return-38.06%-23.47%
1-year return-24.65%-4.73%
5-year return-83.26%-15.71%
P/E ratio (TTM)666.50—
Forward P/E8.87—
EPS (TTM)$0.02$-2.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.20B—
Revenue growth (YoY)+15.58%—
Net income (latest FY)$-713.41M$-119.95M
Gross margin98.84%—
Operating margin-31.83%—
Net margin-32.45%—
52-week high$24.68$40.65
52-week low$13.25$18.25
Distance from 52-week high-45.99%-50.50%
Analyst consensusholdstrong_buy
Avg. price target upside+63.32%+135.83%
Average volume2.70M852.56K
Shares outstanding107.24M69.08M
Employees83587
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TYRA has outperformed SRPT by 19.9 percentage points over the past year.

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

About Tyra Biosciences

TYRA stock →

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

SRPT vs TYRA FAQ

Which is bigger, Sarepta Therapeutics or Tyra Biosciences?

Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.39B for Tyra Biosciences (TYRA).

Which stock has performed better over the past year, SRPT or TYRA?

TYRA returned -4.73% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.

Are Sarepta Therapeutics and Tyra Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons